Home » Topics » BioWorld Science

BioWorld Science
RSS

Positive topline results presented for phase II study of Gazyva in lupus nephritis

June 11, 2019

FDA approves first chemoimmunotherapy regimen for patients with DLBCL

June 11, 2019

Northwestern University presents GBA activators

June 11, 2019

Homology Medicines initiates phase I/II study for HMI-102 gene therapy for adults with PKU

June 11, 2019

Merck & Co. synthesizes new IDO1 inhibitors

June 11, 2019

Hepagene Therapeutics identifies MAP3K5 inhibitors

June 11, 2019

Harvard College and Eisai divulge new compounds for cancer

June 11, 2019

Topline data presented from phase II study of NYX-2925 in patients with fibromyalgia

June 11, 2019

Innovate Biopharmaceuticals initiates first ever phase III study in celiac disease

June 11, 2019

Arvinas patents new IRAK-4-targeting compounds

June 11, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 1, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
New evidence links autoimmunity to long COVID symptoms
BioWorld
Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...
Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections
BioWorld
GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense...